Regeneron Pharmaceuticals, Inc.
REGN
$718.16
-$26.67-3.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 917.70M | 1.34B | 1.43B | 722.00M | 1.16B |
| Total Depreciation and Amortization | 126.40M | 121.70M | 120.70M | 114.10M | 113.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 305.10M | -107.20M | -290.50M | 235.90M | -121.50M |
| Change in Net Operating Assets | -86.40M | -63.90M | -908.50M | 440.50M | -61.40M |
| Cash from Operations | 1.26B | 1.29B | 354.00M | 1.51B | 1.09B |
| Capital Expenditure | -199.60M | -241.90M | -180.50M | -133.90M | -251.40M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 20.10M | -- | -- |
| Cash Acquisitions | -11.50M | 0.00 | -5.00M | -- | -3.80M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 561.70M | -332.50M | -391.80M | -1.55B | 189.00M |
| Cash from Investing | 350.60M | -574.40M | -557.20M | -1.69B | -66.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 90.90M | 254.70M | 437.60M | 682.10M | 301.00M |
| Repurchase of Common Stock | -1.23B | -855.30M | -915.70M | -635.00M | -747.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -33.40M | -- | -- | -- |
| Cash from Financing | -1.14B | -634.00M | -478.10M | 47.10M | -446.10M |
| Foreign Exchange rate Adjustments | -700.00K | 800.00K | -300.00K | -500.00K | 200.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 477.20M | 83.60M | -681.60M | -128.00M | 577.60M |
